Dept. of Internal Medicine (내과학); Kidney Institute (신장연구소)
Keimyung Medical Journal, Vol.25(1) : 1-9, 2006
The incidence of malignancy after renal transplantation is remarkably higher than that in the general population. Therefore, malignancy represents a leading cause of morbidity and mortality in patients with a long-term surviving graft. We reviewed retrospectively the records of
676 patients who received renal transplantation between November 1982 and December 2005 and had been followed for at least 6 months post-transplantation. The overall prevalence of malignancy was 3.0%: five gastrointestinal, four lymphoproliferative diseases, four respiratory tract, two skin cancer, two native renal cell carcinoma, two thyroid, one breast. The mean age at transplantation in the malignancy cases was significantly higher than the other recipients (43.2 ± 10.5 yr vs. 35.4 ± 11.3 yr, p<0.01). The period between transplantation and the diagnosis of
malignancy was 63 ± 36.2 mo (4-161 mo). Twelve patients died with a functioning graft at an
average of 9 mo after diagnosis. In this study, malignancy was third most common cause of death
in renal transplant recipients following infection and vascular accidents. More concern should be
addressed not only to survival of the graft but also to the optimal monitoring of immunosuppression and routine regular examination to diminish the risk of malignancy.